RATIONALE: Asthma is characterized by increases in airway resistance, pulmonary remodeling, and lung inflammation. The cytokine transforming growth factor (TGF)-beta has been shown to have a central role in asthma pathogenesis and in mouse models of allergic airway disease. OBJECTIVES: To determine the contribution of TGF-beta to airway hyperresponsiveness (AHR), we examined the time course, source, and isoform specificity of TGF-beta production in an in vivo mouse asthma model. To then elucidate the function of TGF-beta in AHR, inflammation, and pulmonary fibrosis, we examined the effects of blocking TGF-beta signaling with neutralizing antibody. METHODS: Mice were sensitized and challenged with ovalbumin (OVA) to establish allergic airway disease. TGF-beta activity was neutralized by intranasal administration of monoclonal antibody. MEASUREMENTS AND MAIN RESULTS: TGF-beta1 protein levels were increased in OVA-challenged lungs versus naive controls, and airway epithelial cells were shown to be a likely source of TGF-beta1. In addition, TGF-beta1 levels were elevated in OVA-exposed IL-5-null mice, which fail to recruit eosinophils into the airways. Neutralization of TGF-beta1 with specific antibody had no significant effect on airway inflammation and eosinophilia, although anti-TGF-beta1 antibody enhanced OVA-induced AHR and suppressed pulmonary fibrosis. CONCLUSIONS: These data show that TGF-beta1 is the main TGF-beta isoform produced after OVA challenge, with a likely cellular source being the airway epithelium. The effects of blocking TGF-beta1 signaling had differential effects on AHR, fibrosis, and inflammation. While TGF-beta neutralization may be beneficial to abrogating airway remodeling, it may be detrimental to lung function by increasing AHR.
RATIONALE: Asthma is characterized by increases in airway resistance, pulmonary remodeling, and lung inflammation. The cytokine transforming growth factor (TGF)-beta has been shown to have a central role in asthma pathogenesis and in mouse models of allergic airway disease. OBJECTIVES: To determine the contribution of TGF-beta to airway hyperresponsiveness (AHR), we examined the time course, source, and isoform specificity of TGF-beta production in an in vivo mouseasthma model. To then elucidate the function of TGF-beta in AHR, inflammation, and pulmonary fibrosis, we examined the effects of blocking TGF-beta signaling with neutralizing antibody. METHODS:Mice were sensitized and challenged with ovalbumin (OVA) to establish allergic airway disease. TGF-beta activity was neutralized by intranasal administration of monoclonal antibody. MEASUREMENTS AND MAIN RESULTS:TGF-beta1 protein levels were increased in OVA-challenged lungs versus naive controls, and airway epithelial cells were shown to be a likely source of TGF-beta1. In addition, TGF-beta1 levels were elevated in OVA-exposed IL-5-null mice, which fail to recruit eosinophils into the airways. Neutralization of TGF-beta1 with specific antibody had no significant effect on airway inflammation and eosinophilia, although anti-TGF-beta1 antibody enhanced OVA-induced AHR and suppressed pulmonary fibrosis. CONCLUSIONS: These data show that TGF-beta1 is the main TGF-beta isoform produced after OVA challenge, with a likely cellular source being the airway epithelium. The effects of blocking TGF-beta1 signaling had differential effects on AHR, fibrosis, and inflammation. While TGF-beta neutralization may be beneficial to abrogating airway remodeling, it may be detrimental to lung function by increasing AHR.
Authors: A Niimi; H Matsumoto; R Amitani; Y Nakano; M Mishima; M Minakuchi; K Nishimura; H Itoh; T Izumi Journal: Am J Respir Crit Care Med Date: 2000-10 Impact factor: 21.405
Authors: Bart L Loeys; Junji Chen; Enid R Neptune; Daniel P Judge; Megan Podowski; Tammy Holm; Jennifer Meyers; Carmen C Leitch; Nicholas Katsanis; Neda Sharifi; F Lauren Xu; Loretha A Myers; Philip J Spevak; Duke E Cameron; Julie De Backer; Jan Hellemans; Yan Chen; Elaine C Davis; Catherine L Webb; Wolfram Kress; Paul Coucke; Daniel B Rifkin; Anne M De Paepe; Harry C Dietz Journal: Nat Genet Date: 2005-01-30 Impact factor: 38.330
Authors: G Hansen; J J McIntire; V P Yeung; G Berry; G J Thorbecke; L Chen; R H DeKruyff; D T Umetsu Journal: J Clin Invest Date: 2000-01 Impact factor: 14.808
Authors: Philippe Bonniaud; Peter J Margetts; Martin Kolb; Jane Ann Schroeder; Ann M Kapoun; Debby Damm; Alison Murphy; Sarvajit Chakravarty; Sundeep Dugar; Linda Higgins; Andrew A Protter; Jack Gauldie Journal: Am J Respir Crit Care Med Date: 2004-11-24 Impact factor: 21.405
Authors: Berran Yucesoy; Michael L Kashon; Victor J Johnson; Zana L Lummus; Kara Fluharty; Denyse Gautrin; André Cartier; Louis-Philippe Boulet; Joaquin Sastre; Santiago Quirce; Susan M Tarlo; Maria-Jesus Cruz; Xavier Munoz; Michael I Luster; David I Bernstein Journal: J Immunotoxicol Date: 2015-09-04 Impact factor: 3.000
Authors: Guoping Li; John Fox; Zhigang Liu; Jun Liu; George F Gao; Yang Jin; Hongwei Gao; Min Wu Journal: J Immunol Date: 2013-10-14 Impact factor: 5.422
Authors: Elizabeth A Oczypok; Pavle S Milutinovic; John F Alcorn; Anupriya Khare; Lauren T Crum; Michelle L Manni; Michael W Epperly; Adriane M Pawluk; Anuradha Ray; Tim D Oury Journal: J Allergy Clin Immunol Date: 2015-04-28 Impact factor: 10.793
Authors: L Faustino; D M Fonseca; E B Florsheim; R R Resende; A P Lepique; E Faquim-Mauro; E Gomes; J S Silva; H Yagita; M Russo Journal: Mucosal Immunol Date: 2014-02-26 Impact factor: 7.313
Authors: Julia Freimuth; Frederic F Clermont; Xiaozhu Huang; Angela DeSapio; Taku A Tokuyasu; Dean Sheppard; Rosemary J Akhurst Journal: Proc Natl Acad Sci U S A Date: 2012-10-11 Impact factor: 11.205
Authors: Stephen E Bottoms; Jane E Howell; Alistair K Reinhardt; Iona C Evans; Robin J McAnulty Journal: PLoS One Date: 2010-03-12 Impact factor: 3.240
Authors: Erik P Riesenfeld; Michael J Sullivan; John A Thompson-Figueroa; Hans C Haverkamp; Lennart K Lundblad; Jason H T Bates; Charles G Irvin Journal: Respir Res Date: 2010-02-24